Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.

However, in this trial there was a nonsignificant trend for receptor-positive women to benefit from tamoxifen and for receptor-negative women to do more poorly if given tamoxifen, in terms of both DFS and OS.

also in 5,406 other papers

In the former trials large and highly significant positive effects of OA persisted at 15 years in terms of recurrence (59.0% versus 45.6%; difference = 13.4%, standard error [SE] = 3.2), breast cancer deaths (59.4 versus 49.1%; difference = 10.3%, SE = 3.1), and all deaths (56.7% versus 46.3%; difference = 10.4%, SE = 3.1).

also in 132,142 other papers

In this group of women in the overview, there was a marginally significant improvement in DFS and a trend toward improvement in OS but, because of the relatively small numbers of women studied, the effects in this subgroup are less certain.

also in 26,082 other papers